<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="and Kidney Diseases U01AI096299, U01AI069911, U01AI069924, U01AI069919 http://dx.doi.org/10.13039/100000027National Institute on" exact="Alcohol" post="Abuse and Alcoholism U01AI096299, U01AI069911, U01AI069924, U01AI069919 Strengths and"/>
 <result pre="non-nucleoside reverse transcriptase inhibitor (2NRTIs+1NNRTI). The combination of tenofovir (TDF)," exact="lamivudine" post="(3TC) (or emtricitabine (FTC)) and efavirenz (EFV) is the"/>
 <result pre="inhibitor (2NRTIs+1NNRTI). The combination of tenofovir (TDF), lamivudine (3TC) (or" exact="emtricitabine" post="(FTC)) and efavirenz (EFV) is the current treatment of"/>
 <result pre="combination of tenofovir (TDF), lamivudine (3TC) (or emtricitabine (FTC)) and" exact="efavirenz" post="(EFV) is the current treatment of choice. The phasing"/>
 <result pre="is the current treatment of choice. The phasing out of" exact="stavudine" post="(D4T) and nevirapine (NVP) was almost complete in 2014"/>
 <result pre="treatment of choice. The phasing out of stavudine (D4T) and" exact="nevirapine" post="(NVP) was almost complete in 2014 (table 2). East"/>
</results>
